SCHEMBL6165048

SCHEMBL6165048

CC(CC(=O)O)c1ccc(NC(=O)Cc2ccc3nc(Nc4cccnc4)oc3c2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
POLB P06746 2/20 0.41
USP2 O75604 1/20 0.41
ESR1 P03372 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
ITGB3 P05106 3/20 0.40
ITGAV P06756 3/20 0.40
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
NTRK1 P04629 1/20 0.39
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6165223 0.93 IL6 (0.42) ALDH1A1KDM4EHSD17B10NPC1RAB9A
SCHEMBL6165216 0.93 IL6 (0.42) ALDH1A1KDM4EHSD17B10NPC1RAB9A
SCHEMBL6162294 0.88 KMT2A (0.45) HSD17B10POLBUSP2RAB9AMEN1
SCHEMBL6165644 0.87 HSD17B10 (0.39) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL6165215 0.86 ITGA4 (0.43) TP53CSNK1DITGB1ITGA4
SCHEMBL6162695 0.86 IL6 (0.38) HSD17B10POLBNPC1ADRB2ADRB1
SCHEMBL6163082 0.86 ITGA4 (0.47) POLBNPC1RAB9ASMN1; SMN2TP53
SCHEMBL6165028 0.85 FAAH (0.34) ALDH1A1KDM4EITGB3ITGAVNPC1
SCHEMBL6161296 0.85 SOAT1 (0.40) HSD17B10CSNK1DIL6STAT3ITGB1
SCHEMBL6164611 0.85 CSNK1D (0.42) NPC1RAB9ASMN1; SMN2CSNK1DGALK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1183254-B1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS AVENTIS PHARMA LTD (GB) 2005-01-12 EP disclosed
US-6706738-B2 ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS AVENTIS PHARMA LIMITED (GB) 2004-03-16 US disclosed
US-20020173506-A1 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists AVENTIS PHARMA LIMITED (GB) 2002-11-21 US disclosed
EP-1183254-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS Aventis Pharma Limited (GB) 2002-03-06 EP disclosed
WO-2000061580-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS AVENTIS PHARMA LIMITED (GB) 2000-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173506-A1 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists VCAM1, ITGA4, ITGA1 ALDH1A1 667/4885KDM4E 2729/4885HPGD 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.